A Phase II Study of XL184 (Cabozantinib) for Metastatic Triple-Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2017
Price : $35 *
At a glance
- Drugs Cabozantinib (Primary)
- Indications Advanced breast cancer; Brain metastases
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Exelixis
- 31 Aug 2018 Biomarkers information updated
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 02 Jun 2015 Status changed from recruiting to completed as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.